15

, SHRI SANJAY DALNfIA: The Government is allowing foreign companies to set up joint ventures in fields' like Coca Co I would like to know why the Government does not allow joint venture\* of the Indian companies along with the foreign companies to operate the airlines in India.

SHRI GHULAM NAM AZAD: I have said that as far as foreign equity is concerned, one person has applied so far and we have given permission-to the extent of 40 per cent entity participation of a foreigner.

SHRI SANJAY DALMIA: That was about the NRIs. My' question is about the Indian companies joining hands with foreign companies.

भी गुलाम नदी आजाद : इंडियन्स के लिए तो बिल्कुलं खुला ही खुला है। उसके लिए तो कोई प्राञ्लम ही नहीं है।

## **भी विग्वजय सिंह**ः इनका सवाल कुछ और है ।

SHRI JOHN F. FERNANDES: After repealing the Air Corporation Act, we do not have any statutory body at the moment with a statutory weapon and control. On the contrary we have more airlines. There are fifteen airlines and one domestic carrier, the Indian Airlines. The authority is handicapped because it is exercised by the International Air ports Authority the National Airport Authority and the DGCA. In the absence of any statutory central command and control. I would like to know whether he would see that an Air Transport Board is incorporated so as to control all these airlines.

SHRI GHULAM NABI AZAD: After the repeal of the Act, we have already issued some guidelines and we have also taken the private airlines into confidence. We had a long' meeting with them. On the basis of the consensus on the points which were of 4 mutual interest, they have been incorporated in those guidelines.

We have also said that if at any point of time these guidelines are not adhered to, we would have some quasi-judiciary body to regulatfe the airlines: But it will be as; and when required.'

MR. CHAIRMAN: Q. No. 126.

## Prices of Cephalexin=Based **Formulatfofl**

to Questions

\*I26. SHRI ANANT RAM JAISWAL SHRIMATI SATYA BAHIN:

Will the MINISTER OF CHEMICALS & FERTILIZERS be pleased to state:

- (a) what are the reasons of wide disparities in the prices of Cephalexin-based formulations like Alcepin, Alsporin, Nufex, Phexin Sepexin, Sporidex, etc.:
- (b) what are the market prices in each case and what is the approved price;
- (c) whether it is a fact that overcharging or manipulation of costs at the level of DPRC or its sub-committee is responsible for such a state of affairs; and
- (d) what action Government propose to take to remove these anomalies?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FER-TILIZERS (SHRI EDUARDO FALEIRO): (a) to (d) A Statement is laid on the Table of the House.

## Statement

- (a) There are no disparities in the approved prices of these Cephalexin based formulations.
- (b) To the extent information is available, the market price of Cephalexin based formulations are in accordance with their approved Prices.
  - (c) and (d) Do not arise.

श्री अनन्त राम जायसवाल : सभापति जी क्या मंत्री जी यह बताने की कुपा करेंगे कि सीफेलैंक्सिन और उस पर आधारित वह दवाएं जो कि सवाल के "ए" पार्ट में दे दी गयी है. वह डूग प्राइस कंट्रोल ऑर्डर के तहत आती हैं ? अगर हां, तो क्या सरकार ने उनके दाम घोषित किए हैं अलग-अलग दवाओं के ?

रसायन और उर्वरक मंत्री (श्री राम लखन सिंह यादव) : सभापति जी, 1993 के दिसम्बर महीने से इस पर मुख्य नियंत्रण लाग किया 17

गया है। तद्नुसार 15 दिनों के नोटिस ऐसे सभी कंसन्डं की दिए गए जे इसका जनाव मल्य नियंत्रण कर के दें। उन्होंने इस काम को कर दिया है, लेकिन उसमें अब मूल्य में कोई डिफरेंस भहीं है। कहीं-कहीं है तो जहां एव-साइज इयुटी के चलते जो डिफरेंस पड़ता है वहीं पर असर है अन्यथा सब का मृल्य करीत-करीब बराबर हो गया है।

श्री अमन्त राम आवसवाल : समापति जो, हमने यह पूछा था भि अधन के पार्ट "ए" में दी गयी दवाएं हुग कंट्रोल ऑर्डर के तहत आती हैं ? अगर आती है तो क्या सरकार ने इनके द:म तय किए हैं और अलग-अलग इन दवाओं के दाम पर जो सकार ने तथ किए हैं, वह भ्या है : कृपया यह बताएं।

श्री राम लखन सिंह भादव : ये मृत्य नियं-**त्रण के अंतर्गत अाती है और इसलिए सर**कार ने 15 दिन का नोटिस देकर मूल्य निअंत्रण कर दिया है । अब उसमें कोई और दिक्कत नहीं रह गयी है:

श्री अनन्त राम जायसवाल : सभापति जी, मेरे पहले प्रश्न का जवाब नहीं आया । मैं पूछ रहा हं कि उन दवाओं के सरकार ने क्या वाम घोषित किए, क्या दाम तथ किए है ? संजी जी उसका जवाब तो नहीं दे रहे है।

SHRI EDUARDO FALEIRO: Of course, when we say they are approved prices, there is a price control also on these drugs. As the hon. Member knows very well, the price control applies to drugs which are produced by the companies in the organised sector. So far as drugs produced by the companies in the smallscale sector are concerned, they are exempt from price control.

MR. CHAIRMAN: What are the prices?

SHRI EDUARDO FALEIRO: I am giving the prices, Sir. For instance, the companifcs which are producing these drugs and which are under price control are: Glaxo, Alembic Chemicals, Hoechsft, Lyca and Ranbaxy. 95-M/B(N)16RSS - 2

The prices are: Rs. 16.54 for 250 rag in a pack size of four; Rs. 30.80 for 500 mgina pack size of four. The retail price goes from Rs. 16.54 to Rs. 18.17 and from Rs. 30.84 to Rs. 33.85. As far as our information goes, this is what is being observed.

MR. CHAIRMAN: Please put your second supplementary.

श्री अनन्त राम जायसवास : सगापित जो क्या सरकार बताएगी कि जो दवाएं प्रश्न के पार्ट "ए" में दी गयी है, उनके बाजार भाव क्या है और वाजार भाव अपूब्ड प्राइस में सरकार की निगाह में कोई फर्क है कि नहीं ?

भी राम लखन सिंह यावव : कंट्रोल के बाद मार्केट प्राइस जो अभी तक है, वह पहले 28-12-91 की 18 रुपया 17 पैसे, उसके बाद 35 रूपया 35 पैसे, 17 रूपया 95 पैसे, 33 रुपया 42 पैसे और 21 रुपया 48 पैसे है।

श्रीमती सत्या बहित : भानतीय सभापति जी, माननीय सदस्य ने अपने सवाल में मार्किट रेट पूछा था उन्होंने अपूब्ड प्राइस दी है। तो एक तो यह बास्तविकतः है और इस सदन में भी कई बार इस विषय में चर्चा हो चुकी है और अवाल भी बहुत किए गए है कि मार्केट प्राइस, अपुब्ड प्राइस से **बहुत ज्यादा होती** है । तो डूग प्राइस कंट्रोल एक्ट के अपूबल के मुताबिक वाजारों में दबाइयों की कीमत है या नहीं, ाह सुनिश्चित करने के लिए और उसको हंट्रोल करने के लिए और यह अग़ने के लिए कि यास्तव में अप्रवह रेट से ज्यादा बाजार भाव तो नहीं है, कोई एजेंसी है या क्या इंस्पेक्टर्स जाकर बाजार में इस संबंध में जांच-पड़ताल करते हैं, यह मैं मंत्री महोदय से जानना चाहती ह्रं ?

भी राम लाइन सिंह यादव : सभापति जी अभी जहां तक हम लोगों को जानकारी है उसके नतः(बिक जो हमने प्राइस पिक्स की है, उसमें और मार्केट प्राइस में कोई फर्क नहीं है। फर्क थोड़ा बहुत वहीं है जहांकि एक्साइज इयुटी लगाने 19

का सकाल है और जहां तक इसकी जांच के लिए एजेंसी का सवाल है, यह तही ढंग से चल रही है कि नहीं, तहीं ढंग से व्यापार किया जा रहा है कि, सही ढंग से दाम निर्धारित है, दवा विक रही है कि नहीं, यह देखने का काम पुलिस और हैल्थ डिपार्टमेंट का है जिसके लिए कि उनकी मशीनरी है। हमारे नॉलैंज में जब कोई ऐसी बात आएगी तो हम उनको भेज देंगे।

SHRI RAJN1 RANJAN SAHU: Mr. Chairman, Sir, I am glad that the Minister has announced here, in the House, that the Drug Price Control Order applies to these medicines since December, 1993. Prior to that, the company used to overcharge prices and the consumer had to pay because there was no price fixation before December, 1993.

There is a provision under the DPCO, named as the DPEA, the Drug Price Equalisation Account. The particular medicine is also being manufactured by Glaxo. The Minister has just now said that this particular medicine. which is in question, is also being manufactured by Glaxo. Glaxo is keeping Government money, under the head of DPEA, to the tune of Rs. 100 crores. What steps is the Government taking against this particular company which has already taken overcharge but keeping the money of the Government to the tune of Rs. 100 crores, which is the legitimate money of the Government to be paid by the company? Why has the Government fixed the prices without realising that amount? Why has the company not been charged for the non-payment of the amount with interest, which is lying under the head of DPEA in the name of the company, 'Glaxo'?

SHRI EDUARDO FALEIRO: Sir, under the present DPCO, 1987, the provision for DPEA is not existent. It does not exist. Though it existed under the previous DPCO it does not exist at the moment. And, now when any company overcharges for its products, the present DPCO contemplates that action is to be taken under the Essential Commodities Act. The nodal authorities for taking action are the State Drug Controllers-Action is to be taken under the Essentia<sup>1</sup> Commodities Act. Action has been taken in

several cases and we have got reports from Maharashtra and Gujarat, particularly.

SHRI RAJNI RANJAN SAHU: Sir the Minister is not giving the correct information to the House. He has just now said that the Drug Prices Act has been amended. The Drug Price Control Order has only been amended. It has not been substituted. Under that, the Drug Price Equalisation Account exists. Even today, that account exists in the name of the company.

स्या सरकार व पैता इब नहीं जाता अगर आपने कानन बदल दिया तो ? आपका जी कानन अभी है, इस एक। उन्ह में पिछले दिनों में एक हजार कराड़ रुपशा खोगों पर बाकी है। इस सदन में कई बार यह सवाल उठाया गबा है। अब पिछले पैसे को दबाने के लिए नवा एक्ट अन्य बनाकर उस पैसे को बसूल न करे और बाहे कि असेन्सियल समोटिडिज एक्ट में है, अवर है और असेन्सियल कमो-डिटिश एक्ट अप लागु करना चाहते है तो आपने क्या नोहिस भैजा उस कंपनी का ? उस की प्रोपटी अटैच की ? उस पैसे की रिखाइज करते के लिए सरकार ने क्या किया ?

श्री राम लखन सिंह यादव : महोदय, में भानता हं इस बात को कि माननीय सदस्य की इन सब चीजों की जानकारी हम सबसे ज्यादा प्राप्त है और यह जानते हैं ! इनकी जान-कारी से, जो यह इनफोर्नेशन देंगे उससे हम लाभ उठाएंगे ताकि देश का फायदा हो, लेकिन बरवक्ते अब किसके उधर किलना रुपया बाकी बकाया कब का है, क्यों बकाया है, इनके कहने के रांदर्भ में हम भी अपनी और से यथासंभव जो कानन लाग करें, उस पर देखेंगे कि यह हमें कहां तक सधता है। हम तो मुक्रग्जार होंगे और चंकि में जानता हं कि इनको बहुत जान-कारी है इन सब मामलों में, तो इसलिए इनसे हम लाभ उठाएंगे।

श्री रजनी रंजन साह : हम आपको देगें जानकारी।...

DR. YELAM/VNCHILT STVAJI: Sir, the Minister, in his reply, has stated that all the Cephalexin-based drugs like Alcepin, Alsporin Nufex, Phcxin, etc. which are being marketed in this country are of the same chemical base, 1 he chemicals and the ingredients being the same,. Then, what is the rationale behind the difference in the prices of the various tradenames in the market? Tn the market, so far as my information goes, one tradename is selling at Rs. 14 for four capsules whereas others are selling at Rs. 18 or more. What is the rationale behind the wide variation in the prices of the same chemical produced under different trade-names?

SHRI EDUARDO FALETRO: Sir, I have got all the information. I have a comparative statement of prices of Cephalaxin formulations, giving details for the brand name and the formulation, the company, the strength, the price approved by the Government, the excise duty and the retail prbe charged by the company and it is oar assertion that there is no overcharging. This is our information. T am prepared to give this information to the hon. Member and he will see that there is no difference of any substance.

MR. CHAIRMAN : Q. No. 127. Shri Ashok Mitra.

## Alternative to fertilizer subsidy

\*127. SHRI ASHOK MITRA : SHRI AHMED MOHAMEDBHAI PATEL:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state :

- (a) whether Government are working on an alternative to fertilizer subsidy in the country; if so the deails thereof;
- (b) whether the Parliamentary Committee on the subject has suggested a number of alternatives to subsidy:
- (c) if so, whether, Government have considered the recommendations of the committee in this regard:
- (d) what steps Government propose to take to find out an alternative for subsidy.
- (e) by when final decision is likely to be taken and

(f) What is the amount of the budgetar saving, the alternative subsidy policy aims a achieving on an annual basis?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTI LIZERS (SHRI EDUARDO FALEIRO)

- (a) to (f) A statement is laid on the Table of the House.
- (a) to (f) The terms of reference of the Joint parliamentary Committe? on Fertilize.' pricing wore as fallows:
  - (i) To review the existing method of computation of the Retentation price for different manufacturers of fertilizers and
  - ( ii) to suggest whether there is any scope for reducing fertilizer price within the existing scheme of things, or whether a new methodology for fertilizer pricing should be evolved without causing undue strain to the exchequer, and at the same time assuring fair prices to the farmers and a fair return to the manufacturers."

Some of the recommendations of the Committee like decontrol of phosphatic and potassic fertilizers, abolition of customs duty on imported phosphoric acid and capital goods, and concession in interest rates on loans for setting up new projects were aimed at reducing expenditure on subsidy. Among others, these recommendations have been accepted and implemented.

"8 The revised budgetary provision for subsidy in the current year is Rs. 4,400 crores as against Rs. 5,800 crores in 1992-93.

SHRI ASHOK MITRA: Sir, from the newspaper reports, we are given to understand that the Prime Minister is thinking in terms of an alternative strategy for fertilizer subsidy which goes beyond the recommendations of the Joint -Parliamentary Committee. But I will leave that aside. What is of concern is that the fertilizer subsidy has been slashed from the level of Rs. 5,800 crores in 1992-93 to Rs. 4,400 crores in the current year and the Finance Minister has suggested that next year, there will beafurthercut and the total quantum will be only Rs. 4,000 crores. Lam not at all

†The question was actually asked on the floor House by shri Ashok Mitra.